With regard to HDAC proteins, it is widely documented that HDAC inhibitors inhibit E2 signaling in breast cancer cells by inducing transcriptional repression of ESR1, the ERα-encoding gene, as well as ERα protein degradation (83–88). This evidence concerns the gene HDAC9 and breast carcinoma.